Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a biopharmaceutical company developing therapies using CRISPR gene editing and related technologies, including oligonucleotides and lipid nanoparticles. Its investigational candidates are designed to treat severe diseases by altering their underlying causes. The lead… From the company’s description.
Over the twelve months to Sep 30, 2026, Intellia Therapeutics, Inc. reported revenue of $52.89M, down 8.1% from a year earlier, and a net loss of $426.14M. Its operating margin was −821.2%, and operations used $355.17M in cash. In fiscal 2025, it reported revenue of $67.67M, up 16.9% from fiscal 2024, and a net loss of $412.69M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Intellia Therapeutics, Inc. does
In the company’s own words
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a biopharmaceutical company developing therapies using CRISPR gene editing and related technologies, including oligonucleotides and lipid nanoparticles. Its investigational candidates are designed to treat severe diseases by altering their underlying causes. The lead programs are lonvoguran ziclumeran for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis; both are in Phase 3 development and are designed as one-time intravenous treatments. The company also advances earlier-stage programs independently and with collaborators, including gene-edited cell therapies. Intellia’s work spans in vivo editing, which modifies genes inside the body, and ex vivo approaches that edit cells for therapeutic use. It collaborates with Regeneron on liver-focused CRISPR programs and co-develops nexiguran ziclumeran with Regeneron, which shares development costs and potential commercial profits. Other collaborations include work on universal CAR-T therapies with AvenCell and Kyverna. Intellia is building commercial capabilities as it prepares for potential product launches. It reported no product sales revenue in the fiscal year ended December 31, 2025. Its website is https://www.intelliatx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1652130
- SIC
- 2835
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Intellia Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Intellia Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Intellia Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Intellia Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Intellia Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”